Skip to content

Ovarian Cancer Health Center

Font Size

Ovarian Cancer Screening (PDQ®): Screening - Health Professional Information [NCI] - Overview

Note: Separate PDQ summaries on Ovarian Cancer Prevention; Ovarian Epithelial Cancer Treatment; Ovarian Germ Cell Tumor Treatment; and Ovarian Low Malignant Potential Tumor Treatment are also available.

Evidence of Benefit or Lack of Benefit Associated with Screening

Recommended Related to Ovarian Cancer

General Information About Ovarian Low Malignant Potential Tumors

Ovarian low malignant potential tumor is a disease in which abnormal cells form in the tissue covering the ovary. Ovarian low malignant potential tumors have abnormal cells that may become cancer, but usually do not. This disease usually remains in the ovary. When disease is found in one ovary, the other ovary should also be checked carefully for signs of disease. The ovaries are a pair of organs in the female reproductive system. They are in the pelvis, one on each side of the uterus (the hollow,...

Read the General Information About Ovarian Low Malignant Potential Tumors article > >

Single-threshold cancer antigen 125 (CA-125) levels and transvaginal ultrasound (TVU)

There is solid evidence to indicate that screening for ovarian cancer with the serum marker CA-125 and TVU does not result in a decrease in ovarian cancer mortality, after a median follow-up of 12.4 years.

Magnitude of Effect: The ovarian cancer mortality rate was 3.1 deaths per 10,000 women in the screened group and 2.6 deaths per 10,000 person-years in the usual-care group, yielding a mortality rate ratio of 1.18 (95% confidence interval, 0.82–1.71).

  • Study Design: Evidence obtained from one randomized controlled trial.
  • Internal Validity: Good.
  • Consistency: One trial has evaluated the impact on mortality from ovarian cancer.
  • External Validity: Good.

Statement of Harms

Based on solid evidence, screening for ovarian cancer results in false-positive test results. Screened women had higher rates of oophorectomy and other minor complications, such as fainting and bruising.

Magnitude of Effect:

  • Of screened women, 9.6% had false-positive results, resulting in 6.2% undergoing surgery. The surgical complication rate was 1.2% for all screened women.
  • Oophorectomy rates among screened women compared with usual-care women were 85.7 versus 64.2, respectively per 10,000 person-years.
  • Minor complications with screening: 58.3 cases per 10,000 women screened with CA-125 and 3.3 cases per 10,000 women screened with TVS.
  • Study Design: Evidence obtained from one randomized controlled trial.
  • Internal Validity: Good.
  • Consistency: Not applicable (N/A).
  • External Validity: Good.

References:

  1. Buys SS, Partridge E, Black A, et al.: Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 305 (22): 2295-303, 2011.

WebMD Public Information from the National Cancer Institute

Last Updated: September 04, 2014
This information is not intended to replace the advice of a doctor. Healthwise disclaims any liability for the decisions you make based on this information.
1
Next Article:

Today on WebMD

Ovarian cancer illustration
What are the symptoms?
doctory with x-ray
Get to know the Symptoms.
 
cancer cell
HPV is the top cause. Find out more.
Lung cancer xray
See it in pictures, plus read the facts.
 
Integrative Medicine Cancer Quiz
QUIZ
Lifestyle Tips for Depression Slideshow
SLIDESHOW
 
Screening Tests for Women
Slideshow
Graphic of ovaries within reproductive system
VIDEO
 
Ovarian Cancer Marker
VIDEO
Pets Improve Your Health
SLIDESHOW
 
Vitamin D
SLIDESHOW
Healthy meal with salmon
Article